Venus Remedies Limited — Board Meeting, 01-08-2025: Outcome of Board Meeting

Venus Remedies' board has approved its Q1 consolidated financial results. The company reported a strong jump in net profit to ₹9.60 Cr, significantly up from ₹1.22 Cr in the same period last year. Revenue from operations also rose to ₹131.90 Cr from ₹108.61 Cr. The results included an update on its German subsidiary, Venus Pharma GmbH, which has a negative net worth of ₹2.95 Cr. Management is confident in its revival plans and committed to providing financial support, expecting the situation to stabilize by FY26 end. The company also clarified a pending share application of ₹28.60 Cr for the subsidiary is strategic and will be recovered.